Murase Hideaki, Inokuchi Mikito, Takagi Yoko, Kato Keiji, Kojima Kazuyuki, Sugihara Kenichi
Department of Surgical Oncology, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Department of Translational Oncology, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Mol Clin Oncol. 2014 Jul;2(4):509-517. doi: 10.3892/mco.2014.293. Epub 2014 May 15.
The overexpression of fibroblast growth factor receptor (FGFR) 2 is an established prognostic factor and treatment target in gastric cancer. However, the roles of other FGFRs have not been fully elucidated. In this study, we investigated the correlations of the expression of FGFR1-4 with clinicopathological characteristics and outcomes in gastric cancer. Tumor samples were obtained from 222 patients with gastric adenocarcinoma who underwent gastrectomy between 2003 and 2007. The expression of each FGFR was measured in the tumors by immunohistochemical analysis. The overexpression of FGFR1, FGFR2 or FGFR4 was found to be significantly associated with tumor progression, including depth of invasion, lymph node metastasis, pathological stage and distant metastasis or recurrent disease. Patients exhibiting overexpression of FGFR1, FGFR2 or FGFR4 had a significantly poorer disease-specific survival (DSS; P<0.001, P=0.008 and P<0.001, respectively). Moreover, the co-overexpression of all three FGFRs was significantly associated with a poorer DSS compared to the expression of none or only one of the FGFRs (P<0.001 and P=0.001, respectively) and it was found to be an independent prognostic factor (HR=1.71, 95% CI: 1.02-2.85, P=0.041). In conclusion, high expression of FGFR1, FGFR2 or FGFR4 was associated with tumor progression and poor survival in patients with gastric cancer. Similar to FGFR2, FGFR1 and FGFR4 may be considered as prognostic factors and treatment targets in gastric cancer.
成纤维细胞生长因子受体（FGFR）2的过表达是胃癌中已确定的预后因素和治疗靶点。然而，其他FGFR的作用尚未完全阐明。在本研究中，我们调查了FGFR1 - 4的表达与胃癌临床病理特征及预后的相关性。从2003年至2007年间接受胃切除术的222例胃腺癌患者中获取肿瘤样本。通过免疫组织化学分析测量肿瘤中各FGFR的表达。发现FGFR1、FGFR2或FGFR4的过表达与肿瘤进展显著相关，包括浸润深度、淋巴结转移、病理分期和远处转移或复发性疾病。表现出FGFR1、FGFR2或FGFR4过表达的患者疾病特异性生存率（DSS）显著较差（分别为P<0.001、P = 0.008和P<0.001）。此外，与无FGFR或仅一种FGFR表达相比，所有三种FGFR的共同过表达与较差的DSS显著相关（分别为P<0.001和P = 0.001），并且发现它是一个独立的预后因素（HR = 1.
